Members |
acceptabilityId |
Ca liver - primary |
Acceptable (foundation metadata concept) |
Ca lower third esophagus |
Acceptable (foundation metadata concept) |
Ca middle third esophagus |
Acceptable (foundation metadata concept) |
Ca penis |
Acceptable (foundation metadata concept) |
Ca skin - trunk |
Acceptable (foundation metadata concept) |
Ca splenic flexure - colon |
Acceptable (foundation metadata concept) |
Ca tail of pancreas |
Acceptable (foundation metadata concept) |
Ca transverse colon |
Acceptable (foundation metadata concept) |
Cabbage |
Preferred (foundation metadata concept) |
Cabbage (substance) |
Preferred (foundation metadata concept) |
Cachectic |
Acceptable (foundation metadata concept) |
Cachexia |
Preferred (foundation metadata concept) |
Cachexia (finding) |
Preferred (foundation metadata concept) |
Cadaver allograft heart |
Acceptable (foundation metadata concept) |
Cadaver allotransplant heart |
Acceptable (foundation metadata concept) |
Cafe au lait spots |
Acceptable (foundation metadata concept) |
Cafe-au-lait spots |
Acceptable (foundation metadata concept) |
Caffeine |
Preferred (foundation metadata concept) |
Caffeine (substance) |
Preferred (foundation metadata concept) |
Caffeine citrate |
Preferred (foundation metadata concept) |
Caffeine citrate (substance) |
Preferred (foundation metadata concept) |
Caffeine citrate 20 mg/mL oral solution |
Preferred (foundation metadata concept) |
Caffeine citrate 20 mg/mL solution for injection |
Preferred (foundation metadata concept) |
Caffeine only product |
Preferred (foundation metadata concept) |
Caffeine-related disorder |
Preferred (foundation metadata concept) |
Caffeine-related disorder (disorder) |
Preferred (foundation metadata concept) |
Café au lait spot |
Acceptable (foundation metadata concept) |
Café au lait spot (disorder) |
Preferred (foundation metadata concept) |
Café au lait spots |
Preferred (foundation metadata concept) |
Calamine |
Preferred (foundation metadata concept) |
Calamine (substance) |
Preferred (foundation metadata concept) |
Calamine 150 mg/mL and zinc oxide 50 mg/mL cutaneous lotion |
Preferred (foundation metadata concept) |
Calamine only product |
Preferred (foundation metadata concept) |
Calcaneal region |
Acceptable (foundation metadata concept) |
Calcaneal spur |
Preferred (foundation metadata concept) |
Calcaneal spur (finding) |
Preferred (foundation metadata concept) |
Calcaneal tendon bursa |
Acceptable (foundation metadata concept) |
Calcaneum |
Acceptable (foundation metadata concept) |
Calcaneus |
Acceptable (foundation metadata concept) |
Calciferol |
Acceptable (foundation metadata concept) |
Calcific tendinitis of shoulder |
Preferred (foundation metadata concept) |
Calcific tendinitis of shoulder (disorder) |
Preferred (foundation metadata concept) |
Calcific tendonitis of shoulder |
Acceptable (foundation metadata concept) |
Calcification of breast |
Preferred (foundation metadata concept) |
Calcification of breast (disorder) |
Preferred (foundation metadata concept) |
Calcification of coronary artery |
Preferred (foundation metadata concept) |
Calcification of coronary artery (disorder) |
Preferred (foundation metadata concept) |
Calcifying tendinitis of shoulder |
Acceptable (foundation metadata concept) |
Calcifying tendinitis of the shoulder |
Acceptable (foundation metadata concept) |
Calcinosis cutis, Raynaud's, sclerodactyly AND telangiectasia |
Acceptable (foundation metadata concept) |
Calcinosis, Raynaud phenomenon, sclerodactyly, and telangiectasia (CRST) syndrome |
Acceptable (foundation metadata concept) |
Calcinosis, Raynaud's phenomenon, sclerodactyly, and telangiectasia (CRST) syndrome |
Acceptable (foundation metadata concept) |
Calcinosis, Raynaud's phenomenon, sclerodactyly, and telangiectasia syndrome |
Acceptable (foundation metadata concept) |
Calcinosis, Raynaud's phenomenon, sclerodactyly, and telangiectasia syndrome (disorder) |
Preferred (foundation metadata concept) |
Calcinosis, Raynaud's phenomenon, sclerodactyly, telangiectasia syndrome |
Acceptable (foundation metadata concept) |
Calcium |
Preferred (foundation metadata concept) |
Calcium (substance) |
Preferred (foundation metadata concept) |
Calcium EDTA |
Acceptable (foundation metadata concept) |
Calcium calculus |
Preferred (foundation metadata concept) |
Calcium calculus (morphologic abnormality) |
Preferred (foundation metadata concept) |
Calcium carbonate |
Preferred (foundation metadata concept) |
Calcium carbonate (substance) |
Preferred (foundation metadata concept) |
Calcium carbonate 1.25 g chewable tablet |
Preferred (foundation metadata concept) |
Calcium carbonate 1.25 g oral tablet |
Preferred (foundation metadata concept) |
Calcium chloride |
Preferred (foundation metadata concept) |
Calcium chloride (substance) |
Preferred (foundation metadata concept) |
Calcium chloride 270 microgram/mL and potassium chloride 400 microgram/mL and sodium chloride 6 mg/mL and sodium lactate 3.2 mg/mL solution for infusion |
Preferred (foundation metadata concept) |
Calcium chloride and potassium chloride and sodium chloride and sodium lactate only product |
Preferred (foundation metadata concept) |
Calcium deficiency disease |
Acceptable (foundation metadata concept) |
Calcium disodium edathamil |
Acceptable (foundation metadata concept) |
Calcium disodium edetate |
Acceptable (foundation metadata concept) |
Calcium disodium versenate |
Acceptable (foundation metadata concept) |
Calcium edetate |
Acceptable (foundation metadata concept) |
Calcium folinate |
Acceptable (foundation metadata concept) |
Calcium folinate (substance) |
Preferred (foundation metadata concept) |
Calcium folinate 15 mg oral tablet |
Acceptable (foundation metadata concept) |
Calcium folinate 5 mg oral tablet |
Acceptable (foundation metadata concept) |
Calcium gluconate |
Preferred (foundation metadata concept) |
Calcium gluconate (substance) |
Preferred (foundation metadata concept) |
Calcium gluconate 100 mg/mL solution for injection |
Preferred (foundation metadata concept) |
Calcium gluconate only product |
Preferred (foundation metadata concept) |
Calcium leucovorin |
Preferred (foundation metadata concept) |
Calcium leucovorin 15 mg oral tablet |
Preferred (foundation metadata concept) |
Calcium leucovorin 5 mg oral tablet |
Preferred (foundation metadata concept) |
Calcium metabolism disorder |
Acceptable (foundation metadata concept) |
Calcium only product |
Preferred (foundation metadata concept) |
Calcium pyrophosphate arthritis and periarthritis |
Acceptable (foundation metadata concept) |
Calcium pyrophosphate deposition disease |
Preferred (foundation metadata concept) |
Calcium pyrophosphate deposition disease (disorder) |
Preferred (foundation metadata concept) |
Calcium renal calculus |
Preferred (foundation metadata concept) |
Calcium renal calculus (disorder) |
Preferred (foundation metadata concept) |
Calculation of international normalized ratio |
Preferred (foundation metadata concept) |
Calculation of international normalized ratio (INR) |
Acceptable (foundation metadata concept) |
Calculation of international normalized ratio (procedure) |
Preferred (foundation metadata concept) |
Calculation technique |
Preferred (foundation metadata concept) |
Calculation technique (qualifier value) |
Preferred (foundation metadata concept) |
Calculus |
Preferred (foundation metadata concept) |
Calculus (morphologic abnormality) |
Preferred (foundation metadata concept) |
Calculus - biliary |
Acceptable (foundation metadata concept) |
Calculus in biliary tract |
Acceptable (foundation metadata concept) |
Calculus in biliary tract (disorder) |
Preferred (foundation metadata concept) |